Acrivon therapeutics to present at the oppenheimer 34th annual healthcare life sciences conference

Watertown, mass., feb. 06, 2024 (globe newswire) -- acrivon therapeutics, inc. (“acrivon” or “acrivon therapeutics”) (nasdaq: acrv), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, acrivon predictive precision proteomics (ap3), today announced the company's president and chief executive officer, peter blume-jensen, m.d., ph.d., will participate in a fireside chat on tuesday, february 13, 2024 at 2:40 p.m. et at the oppenheimer 34th annual healthcare life sciences conference.
ACRV Ratings Summary
ACRV Quant Ranking